Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.
Daniel Caldeira, Mariana Alves, Rita Avó-Baião et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effect of aspirin on cardiovascular events in patients with elevated lipoprotein(a) (Lp(a)). Analyzing data from seven studies with 6498 participants, the study found no overall reduction in major adverse cardiovascular events (MACE) with aspirin (HR 0.99, 95% CI 0.79-1.24). However, a significant reduction in myocardial infarction (MI) was observed in rs3798220-C carriers (HR 0.60, 95% CI 0.41-0.88).
Key findings
- Aspirin did not reduce MACE in the overall population (HR 0.99, 95% CI 0.79-1.24).
- In rs3798220-C carriers, aspirin reduced MACE significantly (HR 0.39, 95% CI 0.19-0.77).
- Aspirin significantly reduced MI events (HR 0.60, 95% CI 0.41-0.88).
- Aspirin was associated with a reduction in cardiovascular mortality (HR 0.48, 95% CI 0.28-0.83).
Why it matters
Understanding the role of aspirin in primary prevention for patients with elevated Lp(a) is crucial, as these individuals are at increased cardiovascular risk. The findings suggest that while aspirin may not benefit all, specific genetic variants may influence its effectiveness.
What to keep in mind
Overall certainty of evidence was very low, indicating potential limitations in the reliability of the findings.